BPMC Blueprint Medicines Corporation

81.1
+0.14  (+0%)
Previous Close 80.96
Open 81
Price To Book 7.73
Market Cap 3,990,292,094
Shares 49,202,122
Volume 361,388
Short Ratio
Av. Daily Volume 540,968
Stock charts supplied by TradingView

NewsSee all news

  1. Blueprint Medicines Announces 2020 Corporate Goals

    CAMBRIDGE, Mass., Jan. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  2. Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

    CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  3. Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer

    CAMBRIDGE, Mass., Jan. 8, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  4. CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

    SUZHOU, China and CAMBRIDGE, Mass., Jan. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision

  5. Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested

    CAMBRIDGE, Mass., Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initial data at ASH December 8, 2019 noted robust reductions in serum tryptase. Updated data due 1Q 2020.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
FDA Approval announced January 9, 2020.
Avapritinib BLU-285
PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST)
Phase 1 China enrolment to commence mid-2019.
BLU-554
Advanced hepatocellular carcinoma (HCC)
Phase 1 updated data at ASCO 2019 - 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients. NDA filing due 1Q 2020.
BLU-667 - ARROW
RET-altered solid tumors
Phase 2 updated data due 2H 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
sNDA filing due 2H 2020.
Avapritinib - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 data due 2Q 2020.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 2 trial to be initiated 4Q 2019.
BLU-782
Fibrodysplasia ossificans progressiva (FOP)
Phase 3 trial initiation announced January 13, 2020.
Pralsetinib (BLU-667) - AcceleRET
First-line RET-fusion non-small cell lung cancer (NSCLC)
Rolling NDA has commenced. To be completed 1Q 2020.
Pralsetinib (BLU-667)
First-line RET-fusion non-small cell lung cancer (NSCLC)
Phase 1b/2 trial initiation announced January 6, 2020.
Fisogatinib and CS1001
Hepatocellular Carcinoma
NDA filing due 2Q 2020.
Pralsetinib (BLU-667)
RET-mutant medullary thyroid cancer
PDUFA date under priority review February 14, 2020. However, this will be delayed by up to three months to provide top-line data from VOYAGER trial.
Avapritinib
Fourth-line GIST

Latest News

  1. Blueprint Medicines Announces 2020 Corporate Goals

    CAMBRIDGE, Mass., Jan. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  2. Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

    CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  3. Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer

    CAMBRIDGE, Mass., Jan. 8, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  4. CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

    SUZHOU, China and CAMBRIDGE, Mass., Jan. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision

  5. Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested

    CAMBRIDGE, Mass., Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  6. Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced

  7. Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  8. Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its

  9. Blueprint Medicines to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced